Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06003023 · ClinicalTrials.gov registry record · NA

Congenital Heart Disease Physical Activity Lifestyle Study V.2

A NA study of Heart Defects, Congenital and Cardiovascular Disease Other, sponsored by Jamie Jackson.

Recruiting
Registry status
NA
Development phase
144
Enrollment target
1
Study location

NCT06003023: Recruiting NA study of Heart Defects, Congenital and Cardiovascular Disease Other, sponsored by Jamie Jackson.

NCT06003023 is a NA study of Heart Defects, Congenital and Cardiovascular Disease Other that is actively recruiting participants, run by Jamie Jackson. The registered enrollment target is 144 participants, below the 348-participant average among 9 other Heart Defects, Congenital trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06003023, a NA study of Heart Defects, Congenital and Cardiovascular Disease Other, is actively recruiting participants, sponsored by Jamie Jackson.

RECRUITING
Registry status
NA
Development phase
144 participants
Enrollment target
1
Study location

Study Summary

The Congenital Heart Disease Physical Activity Lifestyle Intervention Study (CHD-PALS) V.2 seeks to determine the efficacy of a lifestyle intervention program for adolescents and young adults (AYAs) with congenital heart disease (CHD). This trial was adapted from the original CHD-PAL trial to continue improving cardiovascular outcomes for transition-aged CHD survivors.

Primary Outcome

Number of minutes spent in moderate to vigorous physical activity as measured by an accelerometer.

Interventions

  • BEHAVIORAL Physical Activity Monitoring
  • BEHAVIORAL Tailored Exercise Prescription
  • BEHAVIORAL Healthy Lifestyle Education
  • BEHAVIORAL Physical Activity Lifestyle Intervention Informed by the Theory of Planned Behavior

Study Locations (1)

Ohio

  • Nationwide Children's Hospital - Columbus

Trial Details

FieldValue
Enrollment Target 144 participants
Start Date 2023-07-18
Est. Completion 2027-06-30
Phase NA
Jamie Jackson

3 total trials

What NCT06003023 shows while recruiting

NCT06003023 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, below the 348-participant average among 9 other Heart Defects, Congenital trials with a reported enrollment target (59% lower).

The record links to 2 conditions, with Heart Defects, Congenital appearing as the primary indexed condition, and to 4 interventions - of which Physical Activity Monitoring is the first listed.

NCT06003023 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT06003023 about?

NCT06003023 is a clinical study titled "Congenital Heart Disease Physical Activity Lifestyle Study V.2". The Congenital Heart Disease Physical Activity Lifestyle Intervention Study (CHD-PALS) V.2 seeks to determine the efficacy of a lifestyle intervention program for adolescents and young adults (AYAs) with congenital heart disease (CHD). This trial was adapted from the original CHD-PAL trial to contin...

What is the current status of trial NCT06003023?

This trial is currently recruiting. It is a NA study. The enrollment target is 144 participants. The study started on 2023-07-18. Estimated completion is 2027-06-30.

What conditions does trial NCT06003023 study?

This clinical trial studies the following conditions: Heart Defects, Congenital, Cardiovascular Disease Other.

What interventions are being tested in trial NCT06003023?

The interventions under investigation include: Physical Activity Monitoring (BEHAVIORAL), Tailored Exercise Prescription (BEHAVIORAL), Healthy Lifestyle Education (BEHAVIORAL), Physical Activity Lifestyle Intervention Informed by the Theory of Planned Behavior (BEHAVIORAL).

Who is sponsoring clinical trial NCT06003023?

This trial is sponsored by Jamie Jackson, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06003023 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Defects, Congenital

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06003023's enrollment target sits among peer trials

144 4th of 9 higher than 6 of 9 other Heart Defects, Congenital trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Heart Defects, Congenital trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01861106 · 144 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations

  • NCT03482245 · 144 participants · NA

    The Role of Circadian Clock Proteins in Innate and Adaptive Immunity

  • NCT03504683 · 144 participants · NA

    MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes

  • NCT03905603 · 144 participants · Early Phase 1

    Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06003023, the US trial registry maintained by the National Library of Medicine. NCT06003023 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.